Michelle Mahler

589 A first in human clinical trial to assess the anti-IL18BP antibody, COM503 (GS-0321) in participants with advanced solid malignancies

Manish Sharma, David Sommerhalder, Drew Rasco, Daniel A. Vaena et autres

us, il (code pays fourni par la source)

1196P COM701 in ovarian cancer: A pooled analysis of 3 phase I clinical trials

Oladapo Yeku, Ryan J. Sullivan, Manish Sharma, Katherine C. Kurnit et autres

us, il (code pays fourni par la source)

985 Triple blockade of DNAM-1axis with COM701(anti-PVRIG)+COM902(anti-TIGIT)+Pembrolizumab shows prelim antitumor activity in pts with platinum resistant ovarian cancer, interim results of phase I trial

Oladapo Yeku, Manish R. Patel, Leigh G. Seamon, Manish Sharma et autres

us, il (code pays fourni par la source)

Preliminary antitumor activity of COM701 in combination with COM902 and pembrolizumab in patients with MSS-CRC and liver metastases.

Manish Sharma, Anne M. Noonan, Daniel A. Vaena, Ecaterina E. Dumbrava et autres

us, il (code pays fourni par la source)

De sorte potter i gråzonen

Michelle Mahler

Abstract CT186: Pharmacokinetic (PK) profile of a novel IKZF1/3 degrader, CFT7455, enables significant potency advantage over other IKZF1/3 degraders in models of multiple myeloma (MM) and the results of the initial treatment cohort from a first-in-human (FIH) phase 1/2 study of CFT7455 in MM

Sagar Lonial, Shambavi Richard, Jeffrey Matous, Andrew J. Yee et autres

us (code pays fourni par la source)

Abstract ND09: The discovery and characterization of CFT8634: A potent and selective degrader of BRD9 for the treatment of SMARCB1-perturbed cancers

Katrina L. Jackson, Roman V. Agafonov, Mark W. Carlson, Prasoon Chaturvedi et autres

Abstract ND13: The discovery and characterization of CFT7455: A potent and selective degrader of IKZF1/3 for the treatment of relapsed/refractory multiple myeloma

James A. Henderson, Scott J. Eron, Andrew C. Good, Ruth Kirby et autres

A Phase 1 Study of CFT7455, a Novel Degrader of IKZF1/3, in Multiple Myeloma and Non-Hodgkin Lymphoma

Jesús G. Berdeja, Sikander Ailawadhi, Steven M. Horwitz, Jeffrey Matous et autres

us (code pays fourni par la source)

Abstract LB007: CFT7455: A novel, IKZF1/3 degrader that demonstrates potent tumor regression in IMiD-resistant multiple myeloma (MM) xenograft models

James A. Henderson, R. Jason Kirby, Samantha Perino, Roman V. Agafonov et autres

no (code pays fourni par la source)

CFT7455: A NOVEL, IKZF1/3 DEGRADER THAT DEMONSTRATES POTENT TUMOR REGRESSION IN A SPECTRUM OF NHL XENOGRAFT MODELS

S. Perino, Bradley Class, Christina S. Henderson, Marta Isasa et autres

us (code pays fourni par la source)

The thrombopoietin mimetic JNJ-26366821 increases megakaryopoiesis without affecting malignant myeloid proliferation

Diego Adrianzen Herrera, Gaurav S. Choudhary, Shanisha Gordon-Mitchell, Nandini Ramachandra et autres

us (code pays fourni par la source)